A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/48 (2006.01) A61K 38/36 (2006.01) A61P 7/04 (2006.01)
Patent
CA 2134750
It has been discovered that it is possible to administer truncated tissue factor, not having the transmembrane region, (tTF) in combination with factor VIIa (FVIIa) or an activator of endogenous factor VII to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10 pg tTF/ml of plasma. The FVIIa or FVII activator is administered to produce levels of between 40 ng VIIa/ml and 700 ng FVIIa/ml of plasma. The effective dosages of both tTF and VIIa/factor VII activator are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.
Comp Philip C.
Morrissey James H.
Kirby Eades Gale Baker
Oklahoma Medical Research Foundation
LandOfFree
Truncated tissue factor and fviia or fvii activator for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Truncated tissue factor and fviia or fvii activator for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Truncated tissue factor and fviia or fvii activator for... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1521461